News

CTI reports topline data for PERSIST-2 in the hopes of lifting FDA hold in coming months.

CTI BIOPHARMA Announces top-line results from PERSIST-2 Phase 3 trial of Pacritnib for high-risk patients with advanced myelofibrosis

ASH announces seventh-round bridge grant recipients

MPN Research Foundation congratulates our MPN Challenge grantees Zhijian Qian, a PhD from the University of Illinois at Chicago and Ann Mullally,a MD at The Brigham and Women's Hospital for receiving the 2016 ASH Bridge Grant.

Anti-fibrotic drug PRM-151 recruiting MF patients across the country

The PROMOTE site has information on their clinical trial including which sites are actively recruiting people who have myelofibrosis.

Stanford and 23andMe partner on MPN

Reported in Blood, 726 people with Polycythemia vera, essential thrombocythemia and myelofibrosis were compared to a control group.

Vice President Joe Biden addresses the 2016 ASCO audience

The Cancer Moonshot is a new push for more teamwork in cancer research and application of innovation.

MPN updates from ASCO 2016

Updates on clinical trials and research news for PV, ET and MF.

Gilead sponsors observational study on MPNs

A research project sponsored by Gilead is currently seeking participants for a study about experience with MPN symptoms.

FDA OK's Pacritinib for some patients; Full clinical hold remains

Pacritinib remains on full clinical hold, but per FDA patients receiving benefit are allowed to receive the drug under a Single Patient IND (SPI)/Compassionate use program.

New research out of UIC suggests racial disparities among those with MPN

Researchers from the University of Illinois at Chicago have just published a study that demonstrated a difference between Caucasians and non-Caucasians for those with myeloproliferative neoplasms.

Medicare has (somewhat) come through for people with Myelofibrosis by agreeing to provide coverage for those who qualify and are in need of a Stem Cell Transplant.

Update: Pacritinib Now on Full Clinical Hold

The FDA has put the Phase 3 trials of Pacritinib on full clinical hold, noting overall survival results.

Zebrafish Shines Light on Melanoma and Provides Hope for MPN

Dr. Leonard Zon of Boston Children's Hospital has made a discovery that shed light on the origins of cancer.

Blood Journal Reports that CALR Mutation Reduced with Pegasys

In the journal Blood, Jean-Jacques Kiladjian and colleagues reported their findings that Pegylated interferon alpha induces hematological and molecular remission in CALR mutated essential thrombocythemia patients.